WallStSmart
BLTE

Belite Bio Inc ADR

NASDAQ: BLTE · HEALTHCARE · BIOTECHNOLOGY

$151.97
-0.77% today

Updated 2026-06-05

Market cap
$5.54B
P/E ratio
P/S ratio
EPS (TTM)
$-2.54
Dividend yield
52W range
$56 – $200
Volume
0.2M

Belite Bio Inc ADR (BLTE) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item202020212022202320242025
Operating cash flow$-4.44M$-7.47M$-11.46M$-29.84M$-29.23M$-36.99M
Capital expenditures$20000.00$74000.00$394000.00$63000.00$151000.00$178000.00
Depreciation
Stock-based comp$1.36M$1.53M$1.48M$3.82M$8.99M$38.92M
Free cash flow$-4.46M$-7.55M$-11.85M$-29.90M$-29.39M$-37.17M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does BLTE generate?

BLTE produced $-37.17M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is BLTE's balance sheet healthy?

BLTE holds $352.93M in cash and equivalents against — in long-term debt, on $770.49M of shareholder equity. That debt is best read against the cash flow the business throws off each year.